{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Neuroprotective Strategies in Coronary Artery Interventions: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were high-risk patients undergoing CABG, TECAB, or hybrid revascularization."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received pharmacological neuroprotection, including barbiturates, volatile anesthetics, lidocaine, NMDA receptor antagonists, magnesium, nimodipine, corticosteroids, and aprotinin, while the control group received standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial was conducted to evaluate neuroprotective strategies in coronary interventions."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of neurological complications within 30 days post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed a significant reduction in complications (mean difference = 5.2%, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the intervention group and 1% in the control group experiencing gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the National Institutes of Health."
      }
    },
    "total_score": 22,
    "max_score": 25
  },
  "model": "gpt-4o"
}